HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).
Sign Up to like & getrecommendations! Published in 2019 at "Clinical immunology"
DOI: 10.1016/j.clim.2019.01.009
Abstract: In Pompe disease, anti-drug antibodies (ADA) to acid alpha-glucosidase (GAA) enzyme replacement therapy contribute to early mortality. Assessing individual risk for ADA development is notoriously difficult in (CRIM-positive) patients expressing endogenous GAA. The individualized T… read more here.
Keywords: antibodies ada; risk; risk developing; drug antibodies ... See more keywords